NYSENYSEARCA:ANVS

Annovis Bio Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Industry, Sector and Symbol

Stock Exchange NYSENYSEARCA
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSENYSEARCA:ANVS
CUSIPN/A
CIKN/A
Phone610 727 3913
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive ANVS News and Ratings via Email

Sign-up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Annovis Bio (NYSENYSEARCA:ANVS) Frequently Asked Questions

What stocks does MarketBeat like better than Annovis Bio?

Wall Street analysts have given Annovis Bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Annovis Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Annovis Bio's key executives?

Annovis Bio's management team includes the following people:
  • Dr. Maria L. MacCecchini, Founder, CEO, Pres & Director (Age 70, Pay $120k)
  • Mr. Jeffrey B. McGroarty CPA, Chief Financial Officer (Age 52)
  • Dr. Jeffrey L. Cummings, Chief Medical Officer & Member of Scientific Advisory Board (Age 71)
  • Dr. William C. Mobley, Chief Scientific Advisor & Member of Scientific Advisory Board

Who are some of Annovis Bio's key competitors?

What is Annovis Bio's stock symbol?

Annovis Bio trades on the New York Stock Exchange (NYSE)New York Stock Exchange (NYSE)ARCA under the ticker symbol "ANVS."

How do I buy shares of Annovis Bio?

Shares of ANVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does Annovis Bio have?

Annovis Bio employs 2 workers across the globe.

What is Annovis Bio's official website?

The official website for Annovis Bio is www.annovisbio.com.

How can I contact Annovis Bio?

The company can be reached via phone at 610 727 3913.


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.